Mepharma SRL
1.2 FTEThe score of Mepharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +69 % Total assets -10 % Headcount (avg FTE) +9 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Mepharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 60,000 € | ||||
| Equity | 453,300 € | ||||
| Cash | 239,479 € | ||||
| EBITDA | 96,326 € | ||||
| Total assets | 701,340 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 25 Sep 2026
- Year ended 31 Dec 2024filed on 12 Aug 2025
- Year ended 31 Dec 2023filed on 17 Sep 2024
- Year ended 31 Dec 2022filed on 15 Nov 2023
- Year ended 31 Dec 2021filed on 25 Nov 2022
Mepharma's financial analysis
- Solvency64.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Mepharma
Mepharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0827.027.443
- VAT number
- BE0827027443
- Peppol
- Registered · 0208:0827027443 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Jun 2010
- Registered office
- 9820 Merelbeke-Melle
- Size
- Micro · 1.2 FTE
- Latest accounts
- 2025 · filed on 25 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Mepharma (SRL) has been based in Merelbeke-Melle since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 60,000 € and equity of 453,300 €; its revenue is not published. With 1.2 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 64.6%, above the median of its sector (44.2%).
Companies similar to Mepharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek De Wachter Retail sale of pharmaceutical products Lede · balance sheet 694,615 €
- Pharmacie Lecompt Retail sale of pharmaceutical products Quaregnon · balance sheet 701,179 €
- West Pharma Retail sale of pharmaceutical products Anderlecht · balance sheet 701,649 €
- Houmanfarma Retail sale of pharmaceutical products Meise · balance sheet 700,955 €
- Apopharma Retail sale of pharmaceutical products Wezembeek-Oppem · balance sheet 702,319 €
- Masy Pharma Retail sale of pharmaceutical products Vilvoorde · balance sheet 700,251 €
- Pharma Cite Retail sale of pharmaceutical products Montigny-le-Tilleul · balance sheet 705,229 €
- AKBM Retail sale of pharmaceutical products Izegem · balance sheet 697,186 €
Frequently asked questions about Mepharma
What is the revenue of Mepharma?
Mepharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Mepharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0827027443 for Mepharma, if the company is VAT-registered. Its company number (CBE) is 0827.027.443.
Where is the registered office of Mepharma?
According to the CBE register, the registered office of Mepharma is in 9820 Merelbeke-Melle.
What is the equity of Mepharma?
At the close of the 2025 financial year, the equity of Mepharma amounts to 453,300 €, a solvency of 64.6% of total assets.
How many people work at Mepharma?
1.2 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Mepharma?
The register lists 1 active mandates at Mepharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Mepharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →